CRISPR Therapeutics Trading Halted Today; FDA Advisory Committee to Review Biologics License Application (BLA) for Exagamglogene Autotemcel (exa-cel) in Sickle Cell Disease (SCD)
31 oct. 2023 07h05 HE
|
CRISPR Therapeutics AG
ZUG, Switzerland and BOSTON, Oct. 31, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...
CRISPR Therapeutics Proposes New Appointment to the Board of Directors
16 oct. 2023 08h00 HE
|
CRISPR Therapeutics AG
ZUG, Switzerland and BOSTON, Oct. 16, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...
CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
27 sept. 2023 09h01 HE
|
CRISPR Therapeutics AG
ZUG, Switzerland and BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...
CRISPR Therapeutics Announces Leadership Transition
07 sept. 2023 08h30 HE
|
CRISPR Therapeutics AG
-CRISPR Therapeutics co-founder, Rodger Novak, M.D., to step down as President and Chairman, effective September 15, 2023--Samarth Kulkarni, Ph.D., to succeed Dr. Novak as Chairman and will continue...
CRISPR Therapeutics to Participate in Citi's 18th Annual Biopharma Conference
30 août 2023 08h00 HE
|
CRISPR Therapeutics AG
ZUG, Switzerland and BOSTON, Aug. 30, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
07 août 2023 16h01 HE
|
CRISPR Therapeutics AG
-FDA accepted Biologics License Applications (BLAs) for exagamglogene autotemcel (exa-cel) for severe Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT); Priority Review for...
CRISPR Therapeutics to Participate in Goldman Sachs 44th Annual Global Healthcare Conference
13 juin 2023 09h00 HE
|
CRISPR Therapeutics AG
ZUG, Switzerland and CAMBRIDGE, Mass., June 13, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
08 mai 2023 16h01 HE
|
CRISPR Therapeutics AG
-Regulatory submissions complete for exagamglogene autotemcel (exa-cel), formerly known as CTX001™, in the U.S. for transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD)- ...
CRISPR Therapeutics to Participate Upcoming Investor Conferences
02 mai 2023 08h00 HE
|
CRISPR Therapeutics AG
ZUG, Switzerland and CAMBRIDGE, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
CRISPR Therapeutics to Participate in Needham’s 22nd Annual Healthcare Conference
13 avr. 2023 16h01 HE
|
CRISPR Therapeutics AG
ZUG, Switzerland and CAMBRIDGE, Mass., April 13, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...